
- Industry news
Industry news
- Category news
- Reports
- Key trends
- Multimedia
Multimedia
- Journal
- Events
- Suppliers
Suppliers
- Home
- Industry news
Industry news
- Category news
- Reports
- Key trends
- Multimedia
Multimedia
- Events
- Suppliers
Suppliers
Kaneka Probiotics: KABP-051 and the future of weight management and psychobiotics
10 Jul 2026 | Kaneka Probiotics
Kaneka Probiotics and AB-Biotics’ latest clinical research on probiotic Lactiplantibacillus plantarum KABP-051 observed modest weight loss alongside improvements mood and energy over 12 weeks, without a diet or exercise plan. Jordi Riera, chief business officer at Kaneka Probiotics, reveals further study details while explaining what a microbiome-based approach means for the future of psychobiotics.
Upcoming webinars

The science of HMOs – A novonesis webinar featuring new clinical findings and ESPGHAN highlights
Novonesis

From boosters to companions: GLP-1 in Food, Beverages and Supplements
Rousselot

Aging Is Inevitable. Longevity Is Negotiable
Sabinsa














